Vertex Pharmaceutica
VRTX
Delayed Nasdaq - 10/23 10:00:00 pm
151.06USD
-2.31%
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 20162017
Sales1 7012 297
EBITDA350482
Operating profit (EBIT)288490
Pre-Tax Profit (EBT)--
Net income-112203
EPS ( $ )-0,460,72
Dividend per Share ( $ )--
Yield--
Announcement Date01/25/2017
09:01pm
-
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 20162017
Debt--
Finance893642
Operating income (EBITDA)350482
Leverage
(Debt/EBITDA)
--
Capital Expenditure70,866,8
Book Value Per Share (BVPS)4,66 $7,43 $
Cash Flow per Share0,96 $1,98 $
Announcement Date01/25/2017
09:01pm
-
Balance Sheet Analysis
Financial Ratios
Size 2017e 2018e
Capitalization 38 985 M$ -
Entreprise Value (EV) 38 343 M$ 37 245 M$
Valuation 2017e 2018e
P/E ratio (Price / EPS) 214x 90,7x
Capitalization / Revenue 17,0x 14,5x
EV / Revenue 16,7x 13,9x
EV / EBITDA 79,6x 42,5x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 20,8x 16,6x
Profitability 2017e 2018e
Operating Margin (EBIT / Sales) 21,3% 31,3%
operating Leverage (Delta EBIT / Delta Sales) 2,00x 4,22x
Net Margin (Net Profit / Revenue) 8,83% 19,8%
ROA (Net Profit / Asset) 9,25% 11,1%
ROE (Net Profit / Equities) 25,9% 23,8%
Rate of Dividend - -
Balance Sheet Analysis 2017e 2018e
CAPEX / CA   2,91% 2,39%
Cash Flow / Sales 21,8% 33,5%
Capital Intensity (Assets / Sales) 0,95x 1,78x
Financial Leverage (Net Debt / EBITDA) -1,33x -1,98x
Price Earning Ratio
BNA & Dividende